Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2009.

At September 30, 2009, the Company had cash, cash equivalents, interest receivable and investment securities of $41.0 million, as compared to $22.7 million at December 31, 2008. On September 30, 2009, the Company completed a $20.0 million registered direct offering of common stock and warrants, which provided proceeds to the Company of approximately $18.4 million, net of offering costs of approximately $1.6 million which were paid subsequent to September 30, 2009.

The net income for the third quarter ended September 30, 2009, was $0.6 million, or $0.01 per diluted share, compared to a net loss of $6.8 million, or $0.15 per diluted share, for the third quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $3.5 million in other revenue, related to the settlement of a dispute with the former licensor of Sulonex (sulodexide), in July 2009, over issues arising from the terminated license agreement, a $1.4 million decrease in other selling, general and administrative expenses, and a $1.4 million decrease in non-cash compensation expense related to equity grants.

The net income for the nine months ended September 30, 2009, was $15.1 million, or $0.31 per diluted share, compared to a net loss of $49.1 million, or $1.11 per diluted share, for the comparable period in 2008. The change in net income (loss) was primarily attributable to a $26.9 million decrease in research and developm
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Physician-Patient Alliance for Health & Safety announced ... the Physician-Patient Alliance Board of Advisors. ... who has practiced in the post-acute care arena since ... on critical patient safety issues. He has represented the ... various conferences addressing the need for patient monitoring and ...
(Date:4/28/2015)... , April 28, 2015  Olympus, a precision technology ... and surgical procedures, among other core businesses, announced today ... Brooklyn Park, MN. The new ... designed to position the company for continued long-term growth ... dedication ceremony took place on April 27 and was ...
(Date:4/28/2015)... , April 28, 2015 A new ... Personal Prescription Importation (CPPI) , has launched today ... prescription medications from Canada ... of Americans – especially the elderly and others ... extremely high price of prescription medications in the ...
Breaking Medicine Technology:Noted Respiratory Therapist and AARC Representative Gene Gantt Joins Physician-Patient Alliance for Health & Safety Advisory Board 2Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 2Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 3Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 4Campaign For Personal Prescription Importation (CPPI), New National Patient Advocacy Organization, Launches Today 2Campaign For Personal Prescription Importation (CPPI), New National Patient Advocacy Organization, Launches Today 3
... The U.S. Food and Drug Administration today is ... that include a new standardized format to improve readability ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Merck,s ... labels for 16 solid oral drug products regulated by ...
... 2011 The U.S. Food and Drug Administration today ... to simultaneously perform a positron emission tomography scan, commonly ... (MRI) scan. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... how the organs and tissues inside the body are ...
Cached Medicine Technology:FDA Approves Redesigned Labels for Some Merck Drugs 2FDA Clears New System to Perform Simultaneous PET, MRI Scans 2FDA Clears New System to Perform Simultaneous PET, MRI Scans 3
(Date:4/28/2015)... Petersburg, FL (PRWEB) April 28, 2015 ... Health System were named to Becker's Hospital Review’s ... Safety . Peter Pronovost, M.D., Ph.D. , director ... Quality and senior vice president for patient safety ... Mueller, M.D., M.H.C.M. , vice president of medical affairs ...
(Date:4/28/2015)... 2015 The popular all-natural supplement brand, ... their newly launched L-Style Revolution Program™, and collectively the ... in just two short months. The customized weight ... plan for men and women of all health and ... and weight maintenance goals faster than traditional methods. , ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 An ... Blair A. Jobe, MD, FACS , has launched the ... tissue with extracellular matrix (ECM) can help patients who ... of esophageal cancer. , ECM is a complex mixture ... attachment and migration and signals that guide cell behavior. ...
(Date:4/28/2015)... As the Muscular Dystrophy Association continues ... the organization has hired Scientific Program Officer Lianna ... Fidelity Biosciences Research Initiative where, as Associate Director, ... diseases such as Alzheimer’s Disease, and organized and ... Fidelity, she was a junior faculty member at ...
(Date:4/28/2015)... 28, 2015 Researchers from four US ... of a steroid prior to pemetrexed (Alimta) chemotherapy may ... Click here to read the full story ... the Raabe College of Pharmacy in Ohio, Stanford Cancer ... Regional Healthcare in Kentucky gave a single dose of ...
Breaking Medicine News(10 mins):Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 2Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 3Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2
... Jersey has its share of underserved children, according to a ... state,s children between 3 and 18 received no dental care ... almost one-third of the state,s children received no care, the ... were still likely to forgo visits to the dentist. ...
... EDITOR,S PICK: Predicting resistance to brain tumor chemotherapy ... lethal of all human brain tumors that originate in ... by both radiation therapy and chemotherapy with temozolomide. However, ... A team of researchers led by Sameer Agnihotri, at ...
... Medicine (BUSM) have identified for the first time the ... target against atherosclerosis resulting from a diet high in ... Circulation , may have significant public health implications. ... at low levels, and at higher levels during exercise ...
... have discovered how malaria manipulates the immune system to allow ... immune system pathway, the research team was able to cure ... published Dec. 11 in the Advance Online Publication of the ... a new approach for treating malaria that does not rely ...
... seedlings is important to crop growth and yield after ... stems, thick leaves, dark green leaves, and large white ... physiology are strongly influenced by the light spectrum, which ... has been shown to increase crop yield after planting ...
... December 11, 2011) Lymphoma and myeloma are both ... blood cells, and commonly involve lymph nodes and the ... the treatment of these diseases, they remain a significant ... unique treatment approaches and targets for lymphoma and myeloma ...
Cached Medicine News:Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 2Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 3Health News:JCI online early table of contents: Dec. 12, 2011 2Health News:JCI online early table of contents: Dec. 12, 2011 3Health News:JCI online early table of contents: Dec. 12, 2011 4Health News:JCI online early table of contents: Dec. 12, 2011 5Health News:JCI online early table of contents: Dec. 12, 2011 6Health News:JCI online early table of contents: Dec. 12, 2011 7Health News:JCI online early table of contents: Dec. 12, 2011 8Health News:JCI online early table of contents: Dec. 12, 2011 9Health News:Researchers identify agent responsible for protection against early stages of atherosclerosis 2Health News:Researchers use new finding to clear bloodstream malaria infection in mice 2Health News:Researchers use new finding to clear bloodstream malaria infection in mice 3Health News:Blue light irradiation promotes growth, increases antioxidants in lettuce seedlings 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 3Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 4Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 5Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 6Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 7Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 8Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 9
... Jenner Stain is used for ... is one of the oldest stain ... provides results similar to that of ... to appear brighter red; basophilic granules ...
Our Reticulocyte Stain is a specialized hematology stain for identifying immature erythrocytes. These immature erythrocytes stain blue in a fine mesh network within the erythrocyte. Mature erythrocyt...
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Medicine Products: